The current model for managing chronic obstructive pulmonary disease (COPD) generally considers inhalers from the same therapeutic class to be clinically equivalent.1 When a long-acting muscarinic ...

The Institute for Clinical and Economic Review (ICER) has published a special report on chronic obstructive pulmonary disease (COPD) therapies as part of the Centers for Medicare & Medicaid Services ...

The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

Illinois Municipal Retirement Fund increased its stake in Innoviva, Inc. (NASDAQ:INVA – Free Report) by 2.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the ...

Many Part D prescription drug plans cover Trelegy Ellipta, but costs can vary by plan type and insurer. Read more.

Medicare Part D prescription drug plans may cover Trelegy Ellipta inhalers. Out-of-pocket costs can vary by plan and insurer, but you may only have to pay a 25% coinsurance. Trelegy Ellipta ...

and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline ...

Meanwhile, sales of the products introduced to replace Advair/Seretide missed consensus estimates, with Breo (fluticasone furoate and vilanterol) bringing in £11 million and Anoro (umeclidinium ...

It’s a blow for GSK, which hopes that Trelegy (fluticasone furoate+umeclidinium+vilanterol) will help to revive the fortunes of its respiratory diseases franchise. The company had been propped ...